Intravesical therapy for bladder cancer

Abstract

This invention relates to an intravesical therapy for bladder cancer.

1 - 24 . (canceled) 
     
     
         25 . A method of therapy for bladder cancer in a bladder cancer patient comprising the instillation into the bladder of said patient of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies. 
     
     
         26 . The method according to  claim 25 , wherein said composition comprises either anti-PD-L1 antibodies or anti-PD-1 antibodies. 
     
     
         27 . The method according to  claim 25 , wherein said composition comprises anti-PD-L1 antibodies and anti-PD-1 antibodies. 
     
     
         28 . The method according to  claim 25 , wherein said anti-PD-L1 antibody is MPDL3280A. 
     
     
         29 . The method according to  claim 25 , wherein said anti-PD-1 antibody is pembrolizumab or nivolumab. 
     
     
         30 . The method according to  claim 25 , wherein the composition comprises a therapeutically effective amount of anti-PD-L1 antibodies and/or anti-PD-1 antibodies. 
     
     
         31 . The method according to  claim 25 , wherein the composition is a semi-solid composition or a liquid composition. 
     
     
         32 . The method according to  claim 31 , wherein the composition is a liquid composition. 
     
     
         33 . The method according to  claim 32 , wherein the composition comprises anti-PD-L1 antibodies and/or anti-PD-1 antibodies in a liquid carrier 
     
     
         34 . The method according to  claim 33 , wherein the liquid carrier is water or an aqueous buffer. 
     
     
         35 . The method according to  claim 31 , wherein the composition is a liquid composition comprising water, the pH of said composition is in the range of 4.5 to 7.5. 
     
     
         36 . The method according to  claim 25 , wherein the composition is instilled into the bladder through a catheter and is left in the bladder from about 20 minutes to about 3 hours. 
     
     
         37 . The method according to  claim 25 , wherein the composition further comprises hexyl 5-ALA ester or a pharmaceutically acceptable salt thereof and wherein after instillation of said composition into the bladder of said patient the inside of said bladder is exposed to light. 
     
     
         38 . The method according to  claim 37 , wherein the concentration of hexyl 5-ALA ester in the composition is in the range of 0.1 to 5% by weight of the total weight of the composition or the equivalent concentration of a pharmaceutically acceptable salt of HAL. 
     
     
         39 . The method according to  claim 38 , wherein the composition is a liquid composition obtained by reconstitution of lyophilized a) anti-PD-L1 antibodies and/or anti-PD-1 antibodies and b) lyophilized hexyl 5-ALA ester or a pharmaceutically acceptable salt thereof in a liquid carrier. 
     
     
         40 . The method according to  claim 39 , wherein the liquid carrier is water or an aqueous buffer. 
     
     
         41 . The method according to  claim 38 , wherein the composition is instilled into the bladder through a catheter and is left in the bladder from about 20 minutes to about 3 hours. 
     
     
         42 . The method according to  claim 38 , wherein the inside of the bladder is exposed to white light and/or blue light and/or red light. 
     
     
         43 . The method according to  claim 42 , wherein the inside of the bladder is exposed to white light followed by blue light. 
     
     
         44 . The method according to  claim 25 , wherein said method is a neoadjuvant therapy for bladder cancer patients who are scheduled for a cystectomy or an adjuvant therapy for bladder cancer patients who undergo transurethral resection (TUR). 
     
     
         45 . The method according to  claim 38 , wherein said method is a neoadjuvant therapy for bladder cancer patients who are scheduled for a cystectomy or an adjuvant therapy for bladder cancer patients who undergo transurethral resection (TUR).